{"disease":{"id":"stroke-prevention","name":"Stroke prevention","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"aspirin-and-dipyridamole","indication_name":"Stroke prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"aspirin and dipyridamole","company_name":"UMC Utrecht","drug_phase":"marketed","molecular_target":"","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Stroke prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"rivaroxaban","indication_name":"Stroke prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."}],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Secondary stroke prevention in older adults","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":3,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04450888","title":"Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":13114,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT04686045","title":"Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Jan Kochanowski University","has_results":false},{"nct_id":"NCT02239120","title":"Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5390,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02156778","title":"Post-Stroke Disease Management - Stroke Card","phase":"NA","overall_status":"COMPLETED","enrollment_count":2149,"lead_sponsor_name":"Medical University Innsbruck","has_results":false},{"nct_id":"NCT06243133","title":"Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Sichuan Provincial People's Hospital","has_results":false},{"nct_id":"NCT01763203","title":"The SUCCEED Trial of Secondary Stroke Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":487,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT06767657","title":"Urgent Carotid Endarterectomy (CEA) Versus Delayed CEA in Symptomatic Carotid Stenosis (SPREAD-STACI II)","phase":"NA","overall_status":"RECRUITING","enrollment_count":456,"lead_sponsor_name":"Italian Society of Vascular and Endovascular Surgery","has_results":false},{"nct_id":"NCT05512546","title":"The Prevention of Thromboembolic Complications Associated With Coil Embolization","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Muhammad Hassan","has_results":false},{"nct_id":"NCT03838341","title":"Stand-alone Totally Thoracoscopic Left Atrial Appendage Occlusion Using AtriClip® Device in Non-valvular Atrial Fibrillation.","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland","has_results":false},{"nct_id":"NCT03923790","title":"Stroke Telemedicine Outpatient Prevention Program for Blood Pressure Reduction","phase":"NA","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":true},{"nct_id":"NCT06580275","title":"The GLACE Study: Evaluating CLAAS With ICE Guided LAA Closure","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Conformal Medical, Inc","has_results":false},{"nct_id":"NCT04273516","title":"Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Mazandaran University of Medical Sciences","has_results":false},{"nct_id":"NCT07257614","title":"Left Atrial Appendage Occlusion in Dialysis Patients With Atrial Fibrillation: A Multicentre Pilot Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Prince of Wales Hospital, Shatin, Hong Kong","has_results":false},{"nct_id":"NCT06820411","title":"A Pilot Study to Assess Optimal Prevention and Outcome Improvement in Young Ischemic Stroke","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","has_results":false},{"nct_id":"NCT06780891","title":"Effectiveness of Telephysical Therapy as a Secondary Stroke Prevention Tool in Patients With Minor Stroke.","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of Cadiz","has_results":false}],"total":15},"guidelines":[{"drug_id":"atorvastatin","guideline_body":"FDA label","recommendation":"To reduce the risk of stroke in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"atorvastatin","guideline_body":"FDA label","recommendation":"To reduce the risk of stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"lipitor","guideline_body":"FDA label","recommendation":"To reduce the risk of stroke in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null},{"drug_id":"lipitor","guideline_body":"FDA label","recommendation":"To reduce the risk of stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD.","line_of_therapy":"1L","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}